Baird analyst Joel Beatty raised the firm’s price target on Immutep (IMMP) to $7 from $6 and keeps an Outperform rating on the shares. The firm raised its target after the company announced investigator initiated INSIGHT-003 study data today for their lead agent eftilagimod alpha (efti).
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.